TScan Therapeutics develops engineered T cell therapies, including TCR-T product candidates that are still in clinical development. TCRX reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 8 | HC Wainwright & Co. | Downgrade | Hold | |
| Sep 3 | Wedbush | Downgrade | Hold | |
| Aug 12 | HC Wainwright & Co. | Reiterated | Buy | |
| Jun 23 | Wedbush | Reiterated | Buy | |
| Jun 23 | Needham | Reiterated | Buy |
Seasonality
How TCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in TCRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TCRX is in one of them and how their past TCRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TCRX in an article yet. Here's the latest on the wider market.
About TScan Therapeutics
TScan Therapeutics is a biological products company based in Waltham, Massachusetts, that develops engineered T cell therapies. Its main focus is a set of TCR-T therapy product candidates, which are still in development and are being studied in clinical trials. These candidates are meant for physicians and the patients they treat, and the company must manufacture them and win regulatory approval before they can be sold. The company relies on contract research organizations, clinical sites and outside manufacturers to carry out its work.
- Headquarters
- Waltham, MA